Landmark Melanoma Vaccine Trial Cuts Recurrence or Death Risk by 42%, Raising Stakes for Cancer Biotech
A first-of-its-kind personalized cancer vaccine has reduced the risk of melanoma recurrence or death by 42% in a landmark trial, according to reports from the European Society for Medical Oncology meeting. The result strengthens the case for individualized immunotherapy and could reshape investor expectations for Moderna, Merck, and the broader oncology biotech sector.
